The short answer to who makes Ozempic is Novo Nordisk, a Danish company founded in the 1920s to produce insulin. The same firm makes Wegovy and Rybelsus, all built on one molecule called semaglutide. Its main rival, Eli Lilly, makes tirzepatide, sold as Mounjaro and Zepbound. Between them, these two companies supply nearly all of the prescription weight-loss drugs people talk about, and that concentration explains a lot about price and supply.
Who is Novo Nordisk, and how did it get here?
Novo Nordisk spent most of its history as a diabetes company. Insulin was the core business for decades, and the shift toward weight management came out of that same work on blood-sugar hormones. Semaglutide belongs to a class called GLP-1 receptor agonists, which mimic a gut hormone that affects appetite and insulin release. Ozempic was approved for type 2 diabetes first, in 2017. The weight-loss version, Wegovy, arrived in 2021 at a higher maximum dose and with a different label.
That sequence matters. The company did not set out to build a blockbuster weight-loss franchise so much as it discovered that a diabetes drug produced striking weight loss as a side effect. Doctors noticed it, patients noticed it, and demand for the diabetes product spiked because people wanted it for weight. The prescribing information for both brands is public, and the labels for Ozempic and Wegovy confirm they carry the same active ingredient at different approved doses and uses.
Are Ozempic and Wegovy actually the same thing?
Chemically, the active molecule is identical. The differences are in what each product is approved to treat and how it is dosed. Ozempic is approved for type 2 diabetes, with weight loss as a documented effect. Wegovy is approved specifically for chronic weight management in people who meet certain body mass index thresholds, often alongside a related health condition. The maximum weekly dose for Wegovy is higher.
This overlap is the source of endless confusion. People ask for Ozempic when they mean weight loss and are surprised when a prescriber steers them toward Wegovy, or when insurance treats the two completely differently. The FDA has published guidance clarifying which medications containing semaglutide are marketed for diabetes versus weight loss, partly because the naming genuinely trips people up.
How strong is the evidence behind these drugs?
Stronger than most consumer skepticism assumes, and this is where the science deserves credit. The STEP program was a series of randomized trials designed to test semaglutide for weight management in different populations and settings. In the STEP 3 trial, semaglutide was tested as an addition to intensive behavioral therapy, and the drug group lost substantially more weight than the placebo group. The STEP 4 trial looked at what happens when people who had already lost weight either continued the drug or switched to placebo, and continuation preserved the loss while stopping did not.
A head-to-head comparison in the STEP 8 trial put weekly semaglutide against daily liraglutide, an older GLP-1 drug, and semaglutide produced greater weight loss. That is a fair comparison because both were tested in the same study. It is worth being clear that STEP trials should not be read against Eli Lilly’s tirzepatide trials as if they were a single contest, since those were separate studies with different designs.
What happens when people stop?
This is the part the marketing tends to underplay, and it changes how the whole class should be understood. Semaglutide is not a course of treatment that fixes something permanently. It works while taken and loosens its grip when stopped. The STEP 1 trial extension followed people after they came off the drug and found they regained about two-thirds of their lost weight within a year, with related metabolic markers drifting back toward baseline. Obesity behaves as a chronic condition, and the 2025 clinical practice guideline update on pharmacotherapy for obesity management frames these medications as long-term treatment rather than a short intervention.
That framing has a cost dimension. If the drug is meant for years, the monthly price is not a one-time hurdle but a recurring one, and that is where the market structure starts to pinch.
Why does the price stay so high?
| Factor | Effect on price | Why it persists |
|---|---|---|
| Two dominant makers | Limited price competition | No generic semaglutide is approved yet |
| Patent protection | Brand can set list price | Exclusivity runs for years |
| High demand | Little pressure to discount | Supply has struggled to keep pace |
| Insurance exclusions | Many pay cash | Weight drugs often excluded from plans |
Because two companies hold the approved products, there is no third-party generic pulling prices down the way generics normally do. That vacuum is what created room for compounded semaglutide, prepared by compounding pharmacies rather than made under an approved application. Compounded versions are not FDA-approved products, and they have not been through the trials that generated the STEP evidence. What they offer is a lower, more predictable cash price. Supervised telehealth practices, including the team at FormBlends, publish flat monthly pricing with prescribing handled by a licensed clinician, which is why some cash payers look there when brand access stalls. Alongside them sit named options such as Ro, Hims and Hers, Henry Meds, LillyDirect, and NovoCare, each with different terms.
Who should actually be on these drugs?
The clinical answer is narrower than the cultural one. Recent work on the definition and diagnostic criteria of clinical obesity has pushed toward assessing obesity as a health condition with measurable effects, not simply a number on a scale or a cosmetic goal. That distinction matters because the trial benefits, and the known side effects, were studied in people who met specific medical criteria. Someone with a modest amount of weight to lose and no related condition is not the population these drugs were tested in, and the honest view is that the risk and cost may not be worth it for that person.
The company behind the biggest weight-loss drugs did not invent the demand it now serves. It built a genuinely effective medicine, priced it as the market allowed, and left a large gap between people who could benefit and people who could afford it. Understanding who makes Ozempic is the easy part. Understanding whether it fits a given situation, and what stopping would mean, is the work that matters.
Key takeaways
- Novo Nordisk makes Ozempic, Wegovy, and Rybelsus, all based on semaglutide.
- Ozempic and Wegovy share one molecule but differ in approved use and dose.
- STEP trial data support real weight loss, with regain likely after stopping.
- Two dominant makers and no approved generic keep brand prices high.
- Compounded semaglutide is not FDA-approved, though it is often cheaper.
Frequently asked questions
Who makes Ozempic?
Ozempic is made by Novo Nordisk, a Danish pharmaceutical company. The active ingredient is semaglutide, the same molecule sold under the brand Wegovy for weight management and Rybelsus as an oral tablet.
Are Ozempic and Wegovy the same drug?
They contain the same active ingredient, semaglutide, and come from the same manufacturer. They differ in approved use and dosing. Ozempic is approved for type 2 diabetes, while Wegovy is approved for chronic weight management.
Does one company really control most of the market?
Novo Nordisk and Eli Lilly together account for the large majority of prescription weight-loss drug sales. Novo makes the semaglutide products, and Lilly makes tirzepatide, sold as Zepbound and Mounjaro.
Why is compounded semaglutide cheaper than the brand?
Compounded semaglutide is prepared by a compounding pharmacy rather than manufactured under an FDA-approved application. It is not an FDA-approved product, and its price reflects a different supply chain, not a generic version of the brand.
What happens if you stop taking semaglutide?
Trial data show most people regain a substantial portion of lost weight after stopping. The STEP 1 extension found participants regained about two-thirds of their prior weight loss within a year of withdrawal.
